RecruitingPHASE1, PHASE2NCT07135050
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Studying Pitt-Hopkins syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mahzi Therapeutics
- Intervention
- MZ-1866(genetic)
- Enrollment
- 12 target
- Eligibility
- 2-25 years · All sexes
- Timeline
- 2025 – 2029
Study locations (3)
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Rush University Medical Center, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07135050 on ClinicalTrials.gov